Drug Type Small molecule drug |
Synonyms APL-1898, APL1898, JS-111 + [1] |
Target |
Mechanism EGFR exon 20 inhibitors(EGFR exon 20 Mutation inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR-mutated non-small Cell Lung Cancer | Phase 2 | CN | 26 Feb 2025 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CN | 14 Jul 2021 | |
EGFR positive non-small cell lung cancer | Phase 2 | CN | 14 Jul 2021 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CN | 13 Jul 2021 | |
metastatic non-small cell lung cancer | Phase 2 | CN | 13 Jul 2021 | |
EGFR ex20ins mutation in non-small cell lung cancer | IND Approval | CN | 22 Feb 2021 |